16. Becton, Dickinson (medical segment)
Revenue: $8,680,000,000*
Headquarters
2019 rank: 16
Employees: 34,000
*Fiscal year ended 9/30/2020
Becton Dickinson saw overall revenue tick down –1% and medical segment sales decline –4% for its most recent fiscal year ended Sept. 30, 2020. BD has grappled not only with the effects of the COVID-19 pandemic but also with a hold on shipments of its Alaris infusion pumps as it prepares a comprehensive 510(k) submission for FDA that covers a host of software fixes needed after a Class I recall. The company expects to submit the 510(k) in late Q2 or early Q3 (around spring 2021), CEO Thomas Polen said during a Nov. 5 earnings call. Meanwhile, the company’s revenue has been helped by the demand for COVID-19 testing, with U.S. HHS even agreeing over the summer to buy 2,000 BD Veritor Plus systems and 750,000 SARS-CoV-2 antigen test kits for use in a broad, decentralized network. Polen said BD expects Veritor testing revenue in a range of $1 billion to $1.5 billion in the 2021 fiscal year. The company also has commitments for over 800 million needles and syringes to deliver future COVID-19 vaccines in the U.S., UK, Canada and elsewhere — a $100 million to $150 million opportunity. –CN
Key personnel: Tom Polen, CEO & president; Vincent Forlenza, executive chair of the board; Simon Campion, EVP, president, interventional segment; Gary Cohen, EVP, global health; Alexandre Conroy, EVP, integrated supply chain; John DeFord, EVP, chief technology officer; Tony Ezell, EVP & chief marketing officer; Jerry Flasz, EVP, global services and chief information officer; Roland Goette, EVP & president, EMEA; Patrick Kaltenback, EVP & president, life sciences segment; Sam Khichi, EVP, general counsel, public policy & regulatory affairs; Betty Larson, EVP & chief human resources officer; James Lim, EVP & president, Greater Asia; Alberto Mas, EVP & president, medical segment; Christopher Reidy, EVP, CFO & chief administrative officer; David Shan, EVP & chief quality officer; William Sigmund, EVP & chief medical officer; Ami Simunovich, EVP & chief regulatory officer